NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with ß-cyclodextrin (Gd2O3@PCD) in MR molecular imaging.

The use of conventional gadolinium(Gd)-based contrast agents in magnetic resonance imaging (MRI) poses a significant risk of Nephrogenic Systemic Fibrosis (NSF) syndrome in patients with impaired renal function (grades 4 and 5). To address this issue, a new study has introduced a novel metabolic Gadolinium oxide nanoparticle (Gd2O3 NPs) coated with ß-cyclodextrin (ßCD). The study aims to investigate NSF syndrome by quantifying tissue Gd deposition biodistribution in renal impairment rats using MR molecular imaging. This is the first study of its kind to use this approach. A group of 20 rats were divided into four groups, each containing five rats that underwent 5/6 nephrectomy. The rats received 12 intravenous injections of a novel homemade synthesized gadolinium oxide polycyclodextrin (Gd2O3@PCD) at a dose of 0.1 mmol/kg, conventional contrast agents (CAs) drugs of Omniscan (Gd-DTPA-BMA) and Dotarem (Gd-DOTA), at a dose of 2.5 mmol/kg, and 250 µl saline for two injections per week during six weeks. T1-weighted MR imaging was performed before the injections and once a week for six weeks to quantify Gd deposition in four different organs (skin, liver, heart, and lung) in rats using inductively coupled plasma mass spectrometry (ICP-MS). The relationship between Signal-to-Noise Ratio (SNR) and biodistribution of Gd deposition due to NSF-induced syndrome was also calculated. The results of the study showed that the Gd concentrations in tissues were significantly higher in the Gd2O3@PCD group compared to the other groups, without any significant histopathological changes (P < 0.05). In the Gd2O3@PCD group, Gd was mainly deposited in the skin, followed by the liver, lung, and heart, without any symptoms of thickening or hardening of the skin. The Gd concentrations in the skin, liver, lung, and heart were significantly lower in the Dotarem group than in the Omniscan group (P < 0.05). In the histopathological examinations, the Omniscan group showed increased cellularity in the dermis. A significant hyperintensity was observed in the Gd2O3@PCD-treated rats compared to the Dotarem and Omniscan groups in the liver, heart, and lung. Compared to conventional Gd-based CAs, the novel metabolically Gd2O3@PCD with increased SNR, biosafety, and a considerably lower probability of developing NSF, has potential applicability for diagnosing patients with renal diseases in clinical MR Molecular Imaging (MRMI).

On The Existence of Nonunique Equilibrium States.

Chemists "know" that the equilibrium position in a homogeneous solution is unique and that the one equilibrium is reached, irrespective of how the solution was prepared. This concept has been verified based on the law of mass action applied to concentrations rather than activities. In this contribution, we explore the situation for a very basic equilibrium system, using established approximations for the activity coefficients. We will demonstrate that under the correct application of the law of mass action, bistable equilibria positions are possible, concomitant, of course, with bifurcation in the kinetics of reaching either of the stable equilibria.

Generalized indicator-based determination of solution pH.

pH indicators can be used both fast responsive as well as long-term stable sensors. They have been extensively used for monitoring pH changes in fast kinetic reactions as well as slowly changing pH in oceanic waters. If the pH range that needs to be covered is narrow it is possible to use only one indicator of appropriate protonation constant; otherwise, mixtures of two or more indicators are used for monitoring pH values covering a broad range of pH. In this paper we presented a new methodology for determining pH of solutions using mixtures of pH indicators. The pH calculation is based on the strict application of the basic laws of mass action and mass conservation. The proposed method was evaluated by the successful determination of the pH values of solutions containing three indicators (neutral red, phenol red (two different protonation constants), and methyl orange) covering a wide range of pH values from 0.5 to 9. The method was also applied for rapid monitoring of pH changes in stopped-flow measurements, investigating the reactions of CO2 in aqueous amine solutions.

Palladium Nanoparticles on a Creatine-Modified Bentonite Support: An Efficient and Sustainable Catalyst for Nitroarene Reduction.

Creatine as the nitrogen-rich, green and cheap compound is used for modification of natural bentonite and the resulting material is employed for the stabilization of Palladium nanoparticles having an average diameter of 3 nm. This new material bento-crt@Pd is characterized using different techniques such as X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), solid state UV-vis, scanning electron microscopy (SEM), transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), thermogravimetric analysis (TGA), and energy-dispersive X-ray spectroscopy (EDX). This green catalyst promotes efficient reduction of aromatic nitro compounds in aqueous media. By using this catalyst nitroarenes having electron donating as well as electron withdrawing groups were reduced efficiently to their corresponding amines at room temperature. The catalyst can be recycled seven times and the reused catalyst was characterized by TEM and XPS.

High doses of oral folate and sublingual vitamin B12 in dialysis patients with hyperhomocysteinemia.

INTRODUCTION: Folic acid and vitamin B12, alone or in combination have been used to reduce homocysteine (Hcy) levels in dialysis patients. OBJECTIVES: We aimed to assess the efficacy of high doses of oral folate and vitamin B12 in reducing plasma Hcy levels after a 12-week treatment. PATIENTS AND METHODS: Thirty-two dialysis patients aged 10-324 months screened for hyperhomocysteinuria. Then cases with hyperhomocysteinemia received oral folate 10 mg/day with sublingual methylcobalamin 1 mg/day for 12 weeks. In pre- and post-intervention phases plasma Hcy concentration, serum folate, and vitamin B12 levels were measured. Changes in plasma Hcy, serum folate, and vitamin B12 concentrations were analyzed by paired t tests, and P values < 0.05 were considered significant. RESULTS: Eighteen (56.2%) patients had hyperhomocysteinuria. Vitamin B12 and folate levels were normal or high in all cases. Two patients were lost due to transplant or irregular drugs consumption. Plasma Hcy levels were reduced in all, and reached normal values in 50%. A statistically significant differences between first Hcy levels with levels after intervention was found (95% CI, 5.1-8.9, P = 0.0001). CONCLUSION: Oral folate 10 mg/day in combination with sublingual vitamin B12, 1 mg/day can be considered as a favorable treatment for hyperhomocysteinemia in dialysis patients.